Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1983 1
1987 1
1990 1
1995 2
2004 1
2007 1
2008 1
2012 1
2013 1
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analys …
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiova …
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ; Collaborative Study Group. Hunsicker LG, et al. Among authors: wiegmann tb. Kidney Int Suppl. 2004 Nov;(92):S99-101. doi: 10.1111/j.1523-1755.2004.09223.x. Kidney Int Suppl. 2004. PMID: 15485429 Free article. Review.
One must use caution in using early changes in proteinuria as a surrogate for longer-term renal outcomes....
One must use caution in using early changes in proteinuria as a surrogate for longer-term renal outcomes....
Decreased Mortality After Long-Term Treatment With Dipeptidyl Peptidase-4 Inhibitors: A Retrospective Study of U.S. Veterans With Type 2 Diabetes.
Cristiano EA, Miles JM, Worsham S, Wiegmann PS, Sharma M, Rakhra V, Goel A, Wiegmann T, Touza MG. Cristiano EA, et al. Among authors: wiegmann t. Endocr Pract. 2022 Jan;28(1):8-15. doi: 10.1016/j.eprac.2021.07.017. Epub 2021 Aug 8. Endocr Pract. 2022. PMID: 34371197 Free article.
Among those with CKD, diabetic nephropathy is the leading cause of end-stage renal disease. This is a retrospective study examining the effect of long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitors on all-cause mortality and progression of renal disease in the veter …
Among those with CKD, diabetic nephropathy is the leading cause of end-stage renal disease. This is a retrospective study examining the effe …
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD; ALLHAT Collaborative Research Group. Margolis KL, et al. Among authors: wiegmann tb. J Clin Hypertens (Greenwich). 2013 Aug;15(8):542-54. doi: 10.1111/jch.12139. Epub 2013 Jun 10. J Clin Hypertens (Greenwich). 2013. PMID: 23889716 Free PMC article. Clinical Trial.
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB; Collaborative Study Group. Heerspink HL, et al. Among authors: wiegmann tb. Nephrol Dial Transplant. 2008 Jun;23(6):1946-54. doi: 10.1093/ndt/gfm893. Epub 2007 Dec 18. Nephrol Dial Transplant. 2008. PMID: 18089623 Clinical Trial.
CONCLUSION: Based on the experience gained in this pilot study, one full-scale trial is currently being conducted to evaluate the effects of sulodexide on change in ACR in patients with persistent microalbuminuria, and a longer-term trial is underway to evaluate the effect …
CONCLUSION: Based on the experience gained in this pilot study, one full-scale trial is currently being conducted to evaluate the effects of …
Effects of Misoprostol on Contrast-Induced Renal Dysfunction.
Gurkowski L, MacDougall M, Wiegmann T. Gurkowski L, et al. Among authors: wiegmann t. Am J Ther. 1995 Nov;2(11):837-842. doi: 10.1097/00045391-199511000-00003. Am J Ther. 1995. PMID: 11854796
Our findings are consistent with a functional role of prostaglandins in the renal response to contrast. We conclude that short-term administration of misoprostol is a useful adjunct for contrast procedures, especially in patients with diabetes and patients on NSAIDs....
Our findings are consistent with a functional role of prostaglandins in the renal response to contrast. We conclude that short-term a …
Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease.
Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study Investigators. Kendrick J, et al. Am J Kidney Dis. 2012 Oct;60(4):567-75. doi: 10.1053/j.ajkd.2012.04.014. Epub 2012 May 22. Am J Kidney Dis. 2012. PMID: 22621970 Free PMC article. Clinical Trial.
OUTCOMES: Death, cardiovascular events, and time to initiation of long-term dialysis therapy. RESULTS: After a median follow-up of 2.9 years, 41% (n = 453) died, whereas 56% (n = 615) initiated dialysis therapy. ...CONCLUSIONS: Low plasma 1,25(OH)(2)D concentrations are as …
OUTCOMES: Death, cardiovascular events, and time to initiation of long-term dialysis therapy. RESULTS: After a median follow-up of 2. …
Comparison of albumin excretion rate obtained with different times of collection.
Wiegmann TB, Chonko AM, Barnard MJ, MacDougall ML, Folscroft J, Stephenson J, Kyner JL, Moore WV. Wiegmann TB, et al. Diabetes Care. 1990 Aug;13(8):864-71. doi: 10.2337/diacare.13.8.864. Diabetes Care. 1990. PMID: 2209321
AER and albumin concentration in spot samples are of limited use for initial screening and frequently require day or 24-h specimens of AER for confirmation. Day or 24-h AER should be used for long-term follow-up of the diabetic patient....
AER and albumin concentration in spot samples are of limited use for initial screening and frequently require day or 24-h specimens of AER f …
The dilemmas of patient treatment for end-stage renal disease.
Schmidt RW, Blumenkrantz M, Wiegmann TB. Schmidt RW, et al. Among authors: wiegmann tb. Am J Kidney Dis. 1983 Jul;3(1):37-47. doi: 10.1016/s0272-6386(83)80008-0. Am J Kidney Dis. 1983. PMID: 6346866
Emphasis upon home dialysis modalities as a method of increasing patient rehabilitation and reducing costs appears to be a short-term necessity. Increased research and development in prevention of ESRD and in achieving better transplant kidney survival appear to be extreme …
Emphasis upon home dialysis modalities as a method of increasing patient rehabilitation and reducing costs appears to be a short-term …
12 results